FTSE MIB
25.892,18 -590,03 (-2,23%) Dow Jones
32.237,53 +132,28 (+0,41%) Nasdaq
11.823,96 +36,56 (+0,31%) Nikkei 225
27.385,25 -34,36 (-0,13%) Petrolio
69,20 -0,76 (-1,09%) Bitcoin EUR
25.588,81 -667,32 (-2,54%)
Bioventus Inc. (BVS)
Dopo ore:
| Chiusura precedente | 1,2900 |
| Aperto | 1,2700 |
| Denaro | 1,2300 x 900 |
| Lettera | 1,3200 x 1100 |
| Min-Max giorno | 1,2300 - 1,3200 |
| Intervallo di 52 settimane | 1,2300 - 14,4900 |
| Volume | |
| Media Volume | 1.327.983 |
| Capitalizzazione | 81,157M |
| Beta (5 anni mensile) | 0,49 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,4500 |
| Prossima data utili | 30 mar 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 6,50 |
- GlobeNewswire
Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2022 before the market opens on Thursday, March 30, 2023. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dia
- GlobeNewswire
Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into a Settlement Agreement (the “Settlement Agreement”) with the former CartiHeal shareholders (the “CartiHeal Sellers”) regarding the Company’s obligations under the amended Option and Equity Purchase Agreement for its prior acquisition of CartiHeal (the “Amended Acquisition Agreement”). The Settlemen
- GlobeNewswire
Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 5:15 p.m. PT (8:15 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 10, 2023. About BioventusBio
